Operaciones Citius Pharmaceuticals, Inc. - CTXR CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.0278 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Citius Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 1.1464 |
| Abrir* | 1.1464 |
| Cambio de 1 año* | 25.98% |
| Rango del día* | 1.1464 - 1.286 |
| Rango de 52 semanas | 0.77-1.71 |
| Volumen medio (10 días) | 1.57M |
| Volumen medio (3 meses) | 29.46M |
| Capitalización de mercado | 174.74M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 158.86M |
| Ingresos | N/A |
| EPS | -0.21 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.38 |
| Próxima fecha de resultados | Aug 9, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 1.1364 | 0.0399 | 3.64% | 1.0965 | 1.1464 | 1.0965 |
| May 30, 2023 | 1.0965 | -0.0100 | -0.90% | 1.1065 | 1.1364 | 1.0965 |
| May 26, 2023 | 1.1065 | 0.0299 | 2.78% | 1.0766 | 1.1165 | 1.0766 |
| May 25, 2023 | 1.0766 | -0.0498 | -4.42% | 1.1264 | 1.1264 | 1.0666 |
| May 24, 2023 | 1.1065 | 0.0200 | 1.84% | 1.0865 | 1.1364 | 1.0666 |
| May 23, 2023 | 1.0965 | -0.0299 | -2.65% | 1.1264 | 1.1464 | 1.0666 |
| May 22, 2023 | 1.1264 | -0.0399 | -3.42% | 1.1663 | 1.1763 | 1.1264 |
| May 19, 2023 | 1.1663 | 0.0199 | 1.74% | 1.1464 | 1.1763 | 1.1264 |
| May 18, 2023 | 1.1165 | 0.0100 | 0.90% | 1.1065 | 1.1564 | 1.0866 |
| May 17, 2023 | 1.0866 | -0.1694 | -13.49% | 1.2560 | 1.2561 | 1.0467 |
| May 16, 2023 | 1.2461 | 0.0000 | 0.00% | 1.2461 | 1.2660 | 1.2261 |
| May 15, 2023 | 1.2660 | -0.1296 | -9.29% | 1.3956 | 1.4056 | 1.2261 |
| May 12, 2023 | 1.3956 | 0.0498 | 3.70% | 1.3458 | 1.4355 | 1.2860 |
| May 11, 2023 | 1.2959 | 0.0199 | 1.56% | 1.2760 | 1.4355 | 1.2760 |
| May 10, 2023 | 1.2461 | 0.0100 | 0.81% | 1.2361 | 1.2860 | 1.1962 |
| May 9, 2023 | 1.2261 | -0.0399 | -3.15% | 1.2660 | 1.2760 | 1.2261 |
| May 8, 2023 | 1.2660 | -0.0100 | -0.78% | 1.2760 | 1.2959 | 1.2461 |
| May 5, 2023 | 1.2660 | 0.0000 | 0.00% | 1.2660 | 1.2959 | 1.2361 |
| May 4, 2023 | 1.2461 | -0.0997 | -7.41% | 1.3458 | 1.3857 | 1.1962 |
| May 3, 2023 | 1.4854 | -0.0099 | -0.66% | 1.4953 | 1.5053 | 1.4654 |
Citius Pharmaceuticals, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Citius Pharmaceuticals Inc Earnings Release Q3 2023 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Ingresos | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 33.3161 | 23.3653 | 17.7107 | 15.5984 | 13.3391 |
| Gastos de venta/general/administración Gastos, total | 15.6606 | 11.2914 | 8.89788 | 7.00146 | 7.22622 |
| Investigación y desarrollo | 17.6555 | 12.2405 | 8.81281 | 8.5969 | 6.56293 |
| Ingresos de explotación | -33.3161 | -23.3653 | -17.7107 | -15.5984 | -13.3391 |
| Ingresos por intereses (gastos), netos No operativos | 0.2514 | 0.25099 | 0.0524 | 0.03622 | -0.01584 |
| Ingresos netos antes de impuestos | -33.0647 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Ingresos netos después de impuestos | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Beneficio neto antes de partidas extra. Elementos | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Ingresos netos | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Beneficio neto diluido | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Promedio ponderado de acciones diluidas | 146.082 | 108.599 | 39.1652 | 20.1618 | 10.7319 |
| BPA diluido sin partidas extraordinarias | -0.23029 | -0.22565 | -0.44805 | -0.77186 | -1.16817 |
| BPA normalizado diluido | -0.23029 | -0.22718 | -0.44805 | -0.77186 | -1.2101 |
| Gastos (ingresos) extraordinarios | 0 | -0.16656 | 0 | -0.45 | |
| Otros, netos | 0 | 0.05992 | 0.11021 | 0 | 0.81834 |
| Total Adjustments to Net Income | 0 | -1.45088 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Ingresos | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 10.6853 | 3.66419 | 7.54957 | 8.91665 | 7.59063 |
| Gastos de venta/general/administración Gastos, total | 5.95845 | 3.80437 | 3.69234 | 4.02846 | 4.13842 |
| Investigación y desarrollo | 4.72686 | 3.44552 | 3.85723 | 4.88819 | 3.45221 |
| Ingresos de explotación | -10.6853 | -3.66419 | -7.54957 | -8.91665 | -7.59063 |
| Ingresos por intereses (gastos), netos No operativos | 0.30328 | 0.21455 | 0.13483 | 0.05302 | 0.02957 |
| Otros, netos | 0 | 0 | |||
| Ingresos netos antes de impuestos | -10.382 | -3.44965 | -7.41474 | -8.86363 | -7.56105 |
| Ingresos netos después de impuestos | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Beneficio neto antes de partidas extra. Elementos | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Ingresos netos | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Beneficio neto diluido | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Promedio ponderado de acciones diluidas | 146.252 | 146.211 | 146.146 | 146.13 | 146.042 |
| BPA diluido sin partidas extraordinarias | -0.07197 | -0.02458 | -0.05468 | -0.06066 | -0.05177 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.07197 | -0.04052 | -0.05468 | -0.06066 | -0.05177 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Gastos (ingresos) extraordinarios | 0 | -3.58569 | 0 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 44.5643 | 72.8143 | 13.982 | 7.94192 | 10.0601 |
| Efectivo e inversiones a corto plazo | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Efectivo y Equivalentes | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Prepaid Expenses | 2.85258 | 2.7414 | 0.12224 | 0.04811 | 0.05773 |
| Total Assets | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Property/Plant/Equipment, Total - Net | 0.65017 | 0.82985 | 0.98778 | 0.00059 | 0.00148 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 1.5868 |
| Intangibles, Net | 59.4 | 59.4 | 19.4 | 19.4 | 19.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.05709 | 0.05709 | 0.00217 |
| Total Current Liabilities | 4.53001 | 3.98229 | 4.09713 | 4.60772 | 3.18484 |
| Accounts Payable | 1.16538 | 1.2771 | 1.85624 | 2.71354 | 1.57344 |
| Accrued Expenses | 3.36463 | 2.7052 | 2.06793 | 1.72121 | 1.43843 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.17297 | 0.17297 | 0.17297 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 11.1734 | 10.2467 | 10.103 | 9.59352 | 3.18484 |
| Total Long Term Debt | 0 | 0 | 0.16458 | 0 | 0 |
| Total Equity | 102.826 | 132.182 | 33.6707 | 27.1529 | 27.8657 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.14621 | 0.14598 | 0.05558 | 0.02893 | 0.0162 |
| Additional Paid-In Capital | 232.368 | 228.084 | 104.209 | 80.1697 | 68.1073 |
| Retained Earnings (Accumulated Deficit) | -129.688 | -96.0478 | -70.5939 | -53.0458 | -40.2578 |
| Total Liabilities & Shareholders’ Equity | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Total Common Shares Outstanding | 146.211 | 145.979 | 55.577 | 28.9305 | 16.1988 |
| Total deudores, neto | 0.81834 | ||||
| Long Term Debt | 0 | 0.16458 | 0 | ||
| Deferred Income Tax | 5.5618 | 4.9858 | 4.9858 | 4.9858 | |
| Other Liabilities, Total | 0.48125 | 0.67823 | 0.85547 | ||
| Minority Interest | 0.60038 | 0.60038 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 34.9011 | 42.3174 | 44.5643 | 50.8345 | 58.2593 |
| Efectivo e inversiones a corto plazo | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Efectivo y Equivalentes | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Prepaid Expenses | 5.8356 | 5.43013 | 2.85258 | 2.79032 | 2.50311 |
| Total Assets | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Property/Plant/Equipment, Total - Net | 0.55484 | 0.60299 | 0.65017 | 0.69642 | 0.74177 |
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 9.3468 |
| Intangibles, Net | 59.4 | 59.4 | 59.4 | 59.4 | 59.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.03806 | 0.03806 | 0.03806 |
| Total Current Liabilities | 6.20968 | 4.53717 | 4.53001 | 4.46112 | 4.02192 |
| Accounts Payable | 2.72559 | 1.53758 | 1.16538 | 1.69052 | 1.70513 |
| Accrued Expenses | 3.48408 | 2.99959 | 3.36463 | 2.7706 | 2.3168 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.0347 | 11.2719 | 11.1734 | 10.5802 | 10.1904 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Deferred Income Tax | 5.8498 | 5.7058 | 5.5618 | 4.9858 | 4.9858 |
| Minority Interest | 0.60038 | 0.60038 | 0.60038 | 0.60038 | 0.60038 |
| Other Liabilities, Total | 0.37483 | 0.42857 | 0.48125 | 0.53288 | 0.5823 |
| Total Equity | 91.2061 | 100.433 | 102.826 | 109.736 | 117.596 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.14636 | 0.14621 | 0.14621 | 0.14613 | 0.14613 |
| Additional Paid-In Capital | 234.868 | 233.569 | 232.368 | 231.287 | 230.284 |
| Retained Earnings (Accumulated Deficit) | -143.808 | -133.282 | -129.688 | -121.698 | -112.834 |
| Total Liabilities & Shareholders’ Equity | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Total Common Shares Outstanding | 146.358 | 146.211 | 146.211 | 146.13 | 146.13 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Efectivo de actividades de explotación | -28.3613 | -24.2504 | -16.9307 | -12.4377 | -11.3181 |
| Efectivo de actividades de explotación | 0.00292 | 0.00149 | 0.00084 | 0.00089 | 0.00175 |
| Partidas no monetarias | 4.46091 | 1.5198 | 1.48355 | 0.92758 | 0.7069 |
| Cash Taxes Paid | |||||
| Intereses pagados en efectivo | 0 | 0.00019 | |||
| Cambios en el capital circulante | 0.23956 | -2.71727 | -0.86697 | 2.19592 | 0.50985 |
| Efectivo de actividades de inversión | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Otras partidas de flujo de caja de inversión, total | 0 | ||||
| Efectivo procedente de actividades de financiación | 0 | 120.471 | 22.8984 | 11.1475 | 17.298 |
| Elementos de flujo de caja de financiación | 0 | 18.4504 | 0 | 0 | |
| Emisión (amortización) de deuda, neta | 0 | -0.17297 | 0.16458 | 0 | 0 |
| Variación neta de la tesorería | -28.3613 | 56.2132 | 5.96594 | -1.2902 | 5.9799 |
| Gastos de capital | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Emisión (retiro) de acciones, neto | 0 | 102.193 | 22.7339 | 11.1475 | 17.298 |
| Deferred Taxes | 0.576 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.1197 | -3.59365 | -33.6407 | -25.6499 | -16.7863 |
| Cash From Operating Activities | -12.6774 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Operating Activities | 0.00146 | 0.00073 | 0.00292 | 0.00219 | 0.00146 |
| Non-Cash Items | 2.56255 | 1.24754 | 4.46091 | 3.3344 | 2.28611 |
| Changes in Working Capital | -1.40977 | -2.62306 | 0.23956 | 0.28456 | 0.18199 |
| Cash From Financing Activities | 0.03127 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03127 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -12.6462 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Deferred Taxes | 0.288 | 0.144 | 0.576 | ||
| Other Investing Cash Flow Items, Total | 0 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Mazur (Leonard L) | Individual Investor | 6.4557 | 10255342 | -1 | 2022-11-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8112 | 6054328 | 40301 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.5265 | 2425000 | -3743361 | 2021-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4586 | 2317168 | 4868 | 2023-03-31 | LOW |
| Holubiak (Myron Z) | Individual Investor | 1.2541 | 1992243 | 0 | 2022-11-30 | |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8428 | 1338777 | 6154 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3 | 476597 | 34000 | 2023-03-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2893 | 459511 | 130223 | 2023-03-31 | MED |
| GSA Capital Partners LLP | Hedge Fund | 0.2849 | 452561 | -46222 | 2023-03-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.2513 | 399270 | -9900 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.1917 | 304482 | -246644 | 2023-03-31 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.1549 | 246023 | 224990 | 2023-03-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1541 | 244755 | 7008 | 2023-03-31 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.1317 | 209198 | 14713 | 2023-03-31 | LOW |
| Inspire Advisors, LLC | Investment Advisor | 0.125 | 198632 | 2686 | 2023-03-31 | LOW |
| Wealth Advisory Solutions, L.L.C. | Investment Advisor | 0.0981 | 155850 | 0 | 2023-03-31 | |
| AHL Partners LLP | Investment Advisor | 0.0836 | 132826 | 86615 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0759 | 120521 | 31943 | 2023-03-31 | MED |
| Qube Research & Technologies Ltd | Hedge Fund | 0.063 | 100106 | -20474 | 2023-03-31 | HIGH |
| Kestra Advisory Services, LLC | Investment Advisor | 0.0579 | 91917 | -1800 | 2023-03-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Citius Pharmaceuticals, Inc. Company profile
Sobre Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc. empresa farmacéutica especializada. La empresa desarrolla y comercializa productos de cuidados intensivos centrados en productos antiinfecciosos para el tratamiento del cáncer, productos de prescripción y terapia con células madre mesenquimales. Cuenta con cinco productos: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite e I/ONTAK. Mino-Lok es una solución de bloqueo de antibióticos que se utiliza para tratar a pacientes con infecciones del torrente sanguíneo relacionadas con catéteres, salvando el catéter infectado. Mino-Wrap es una envoltura a base de gel licuado para reducir las infecciones por expansores tisulares tras cirugías reconstructivas de mama. Halo-Lido es una formulación tópica de corticosteroides-lidocaína, destinada a proporcionar un alivio antiinflamatorio y anestésico a las personas que padecen hemorroides. NoveCite es una terapia con células madre mesenquimales para el tratamiento del SDRA. I/ONTAK es una proteína de fusión de IL-2 con toxina diftérica, para el tratamiento de pacientes con linfoma cutáneo de células T persistente o recurrente.
El precio actual de la acción Citius Pharmaceuticals, Inc. en tiempo real es 1.24 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Balfour Beatty PLC, Valuetronics, Brenntag AG, CohBar, Inc., Vimeo, Inc. y MoSys. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com